Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

This study is closely monitoring patients with a type of blood cancer (B-cell lymphoma) who are receiving a specialized treatment called CAR T cell therapy — where a patient's own immune cells are modified in the lab to fight cancer. Researchers want to learn more about why some patients respond better than others by collecting blood and biopsy samples at different stages. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with relapsed or refractory B-cell lymphoma (cancer that has come back or stopped responding to treatment) - You are already planned to receive CAR T cell therapy as part of your standard care - You are willing to donate blood and tissue samples at scheduled visits **You may NOT be eligible if...** - You have a condition that prevents you from receiving CAR T cell therapy (e.g., active infection, pregnancy) - You have another medical or psychological condition that would prevent you from completing study procedures - You are unwilling or unable to follow the study protocol Talk to your doctor to see if this trial is right for you.